The role of alpha7 nicotinic acetylcholine receptors in inflammatory bowel disease: involvement of different cellular pathways. (1st February 2018)

• Record Type: Journal Article
• Authors: Seyedabadi, Mohammad; Rahimian, Reza; Ghia, Jean-Eric
• Is Part Of: Expert opinion on therapeutic targets. Volume 22:Number 2(2018:Feb.)
• Page Start: 161
• Page End: 176
• Publication Date: 2018-02-01
• Subjects: α7nAChR -- inflammatory bowel disease -- immune cells -- cytokines -- intracellular pathways; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2018.1420166
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Autonomic imbalance plays a pivotal role in the pathophysiology of inflammatory bowel diseases (IBD). The central nervous system (CNS) cooperates dynamically with the immune system to regulate inflammation through humoral and neural pathways. In particular, acetylcholine (Ach), the main neurotransmitter in the vagus nerve, decreases the production of pro-inflammatory cytokines through a mechanism dependent on the α7 nicotinic Ach receptors (α7nAChRs). Areas covered : Here, we review the evidence for involvement of the cholinergic anti-inflammatory pathway (CAP) in IBD. We also elaborate the role of α7nAChRs and subsequent cellular pathways in CAP. Finally, we review potential therapeutic implications of modulators of these receptors. Expert opinion : Alpha7nAChR modulators possess both cognitive improving and anti-inflammatory properties. Although, these agents demonstrated therapeutic benefits in experimental models, their efficacy has not always been translated in clinical trials. Thus, development of more specific α7nAChR ligands as well as more experimental studies and better controlled trials, especially in the field of IBD, are encouraged for a progress in this field.